Benzimidazole anthelmintics exhibit synergistic effects when combined with standard cancer therapies, including ionizing radiation, traditional chemotherapeutics, targeted signal inhibitors, and efflux pump blockers.
1. Synergy with Ionizing Radiation (Radiotherapy)
Benzimidazoles act as radiosensitizers through both mitotic and interphase mechanisms:
Inhibition of DNA Damage Repair: Mebendazole (MBZ) hinders the trafficking of key DNA damage response proteins (such as Chk2 and Nbs1) from the cytoplasm to the nucleus following radiation. This leads to sustained double-strand DNA breaks (elevated γH2AX levels).
Preclinical Efficacy:
In intracranial rodent models of malignant meningioma, combining MBZ with local radiation significantly extended median survival, delayed tumor growth, decreased the angiogenesis marker CD31, and elevated apoptotic cleaved caspase-3 compared to either treatment alone.
In triple-negative breast cancer (TNBC), MBZ potentiated radiotherapy, suppressed the radiation-induced conversion of bulk cancer cells into self-renewing cancer stem cells, and inhibited the Hedgehog survival pathway.
In glioblastoma (GL261, GBM14), MBZ significantly increased the radiation dose enhancement factor. (Note: In contrast, Fenbendazole did not show radiosensitization in EMT6 mouse mammary tumor models).
2. Synergy with Standard Chemotherapeutic Agents
Benzimidazoles enhance cytotoxicity and help resensitize chemoresistant tumor cells across multiple chemotherapeutic classes:
Vinca Alkaloids (vinblastine, vincristine): Flubendazole (FLBZ) binds tubulin at a site distinct from vinblastine and remains effective against P-glycoprotein (P-gp)-overexpressing, vinblastine-resistant cells. Combining FLBZ with vinblastine or vincristine produces strong synergistic cell killing in leukemia (OCI-AML2) and myeloma models, significantly reducing tumor burden in xenografts without added systemic toxicity.
Platinum Agents (cisplatin, carboplatin):
MBZ resensitizes cisplatin-resistant ovarian cancer cells by downregulating pro-survival pathways (NF-κB, MYC, ELK/SRF, E2F), resulting in blunted tumor growth in cisplatin-resistant xenograft models.
In head and neck squamous cell carcinoma (HNSCC) and urothelial carcinoma, MBZ/FBZ combined with cisplatin or carboplatin enhances cell death and reduces tumor volume.
Alkylating Agents (temozolomide): Combining MBZ with temozolomide (TMZ) significantly extends overall survival in glioblastoma and high-grade glioma models—including TMZ-tolerant and TMZ-resistant intracranial tumors.
Taxanes & Antimetabolites (docetaxel, paclitaxel, gemcitabine, 5-FU): MBZ synergizes with docetaxel in prostate cancer models, while FLBZ and Albendazole (ABZ) show synergistic antiproliferative effects with paclitaxel in colorectal and leukemia models. Parbendazole and MBZ also demonstrate synergy with gemcitabine in pancreatic and HER2+ breast cancer models.
3. Combination with Targeted Inhibitors & Bioavailability Enhancers
MEK / BRAF Pathway Inhibitors (trametinib, sorafenib): MBZ combined with the MEK inhibitor trametinib suppresses refractory NRAS-mutated melanoma by completely abrogating MEK1/2 and ERK1/2 phosphorylation. MBZ also augments sensitivity to sorafenib in hepatocellular carcinoma (HCC) via downregulating MAPK and BCL-2 signaling.
Metabolic Inhibitors (dichloroacetate / DCA): In non-small cell lung cancer (A549 xenografts), combining Fenbendazole with diisopropylamine dichloroacetate (DADA/DCA) achieved a 50% complete tumor regression rate compared to 0% with FBZ alone and 11.1% with DADA alone.
Efflux Pump Inhibitors (elacridar): Because central nervous system drug penetration is restricted by P-gp and BCRP efflux pumps, co-administering MBZ (polymorph C) with the efflux inhibitor elacridar dramatically increases MBZ brain distribution and extends median survival from 53–52 days up to 110.5–77 days in orthotopic glioma (GL261) and medulloblastoma (D425) xenograft models.
Immune Checkpoint Inhibitors: Clinical case reports document complete or near-complete remissions when incorporating Fenbendazole alongside anti-PD-1 immunotherapies like pembrolizumab or nivolumab in urothelial, melanoma, and advanced solid tumors.
References
Abughanimeh, O., Evans, T., & Kallam, A. (2020). Fenbendazole as a treatment for diffuse large B-cell lymphoma. Annals of Hematology & Oncology, 7(2), Article 1284.
Bai, R.-Y., Staedtke, V., Aprhys, C. M., Gallia, G. L., & Riggins, G. J. (2011). Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro-Oncology, 13(9), 974–982. [suspicious link removed]
Bai, R.-Y., Staedtke, V., Rudin, C. M., Bunz, F., & Riggins, G. J. (2015). Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. Neuro-Oncology, 17(4), 545–554. [suspicious link removed]
Bai, R.-Y., Staedtke, V., Wanjiku, T., Rudek, M. A., Joshi, A., Gallia, G. L., & Riggins, G. J. (2015). Brain penetration and efficacy of different mebendazole polymorphs in a mouse brain tumor model. Clinical Cancer Research, 21(15), 3462–3470. https://doi.org/10.1158/1078-0432.CCR-14-2681
Bieging, K. T., & Attardi, L. D. (2012). Deconstructing p53 transcriptional networks in tumor suppression. Trends in Cell Biology, 22(2), 97–106. [suspicious link removed]
de la Torre-Iglesias, P. M., García-Rodriguez, J. J., Torrado, G., Torrado, S., Torrado-Santiago, S., & Bolás-Fernández, F. (2014). Enhanced bioavailability and anthelmintic efficacy of mebendazole in redispersible microparticles with low-substituted hydroxypropylcellulose. Drug Design, Development and Therapy, 8, 1467–1479. [suspicious link removed]
De Witt, M., Gamble, A., Hanson, D., Markowitz, D., Powell, C., Al-Ahmadie, H. A., & Symons, M. (2017). Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors. Molecular Medicine, 23, 50–56. [suspicious link removed]
Ding, Y., Zhang, Z., Ding, C., Xu, S., & Xu, Z. (2024). Preparation and evaluation of fenbendazole methyl-β-cyclodextrin inclusion complexes. BMC Veterinary Research, 20(1), Article 214. [suspicious link removed]
Duan, Q., Liu, Y., & Rockwell, S. (2013). Fenbendazole as a potential anticancer drug. Anticancer Research, 33(2), 355–362.
Freisleben, F., Modemann, F., Muschhammer, J., Stamm, H., Brauneck, F., Krispien, A., Bokemeyer, C., Kirschner, K. N., Wellbrock, J., & Fiedler, W. (2021). Mebendazole mediates proteasomal degradation of GLI transcription factors in acute myeloid leukemia. International Journal of Molecular Sciences, 22(19), Article 10670. [suspicious link removed]
Gao, P., Dang, C. V., & Watson, J. (2008). Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins. Journal of the American Association for Laboratory Animal Science, 47(6), 37–40.
Garona, J., Pifano, M., Scursoni, A. M., Gomez, D. E., Alonso, D. F., & Ripoll, G. V. (2020). Repurposing of anthelmintic and antiparasitic drugs in oncology. International Journal of Oncology, 56(3), 651–680. [suspicious link removed]
Golla, U., Patel, S., Shah, N., Talamo, S., Bhalodia, R., Claxton, D., Dovat, S., & Sharma, A. (2024). From deworming to cancer therapy: Benzimidazoles in hematological malignancies. Cancers, 16(19), Article 3454. [suspicious link removed]
Guerini, A. E., Triggiani, L., Maddalo, M., Bonù, M. L., Frassine, F., Baiguini, A., Alghisi, A., Tomasini, D., Borghetti, P., Pasinetti, N., Biti, G., & Magrini, S. M. (2019). Mebendazole as a candidate for drug repurposing in oncology: An extensive review of current literature. Cancers, 11(9), Article 1284. [suspicious link removed]
Huang, L., Zhang, L., Zhang, J., Zhao, L., He, F., Wang, H., Liu, Q., Shi, D., Ni, N., Shu, Y., Zeng, Z., Huang, B., Huang, S., Lei, Y., Ye, Z., Cao, D., Yang, L., Wu, D., Feng, Y., ... He, T.-C. (2021). Mebendazole sensitizes chemoresistant human ovarian cancer cells to cisplatin-induced cytotoxicity and tumor growth inhibition. Aging (Albany NY), 13(18), 22305–22325. [suspicious link removed]
Joe, N. S., Wang, Y., Oza, H. H., Godet, I., Milki, N., Riggins, G. J., & Gilkes, D. M. (2023). Mebendazole treatment disrupts the transcriptional activity of hypoxia-inducible factors 1 and 2 in breast cancer cells. Cancers, 15(4), Article 1330. [suspicious link removed]
Karimi, A., Barea, P., Benito-Román, Ó., Blanco, B., Sanz, M. T., Higginbotham, C. L., & Lyons, J. G. (2025). Investigation of fenbendazole solubility using particle size reduction methods in the presence of Soluplus®. Pharmaceutics, 17(9), Article 1163. [suspicious link removed]
Larsen, A. R., Bai, R.-Y., Chung, J. H., Borodovsky, A., Rudin, C. M., Riggins, G. J., & Bunz, F. (2015). Repurposing the antihelmintic mebendazole as a hedgehog inhibitor. Molecular Cancer Therapeutics, 14(1), 3–13. [suspicious link removed]
Laudisi, F., Marônek, M., Di Grazia, A., Monteleone, G., & Stolfi, C. (2020). Repositioning of anthelmintic drugs for the treatment of cancers of the digestive system. International Journal of Molecular Sciences, 21(14), Article 4957. [suspicious link removed]
Lei, X., Wang, Y., Chen, Y., Duan, J., Gao, X., & Cong, Z. (2025). Fenbendazole exhibits antitumor activity against cervical cancer through dual targeting of cancer cells and cancer stem cells: Evidence from in vitro and in vivo models. Molecules, 30(11), Article 2377. [suspicious link removed]
Li, Y., Thomas, D., Deutzmann, A., Majeti, R., Felsher, D. W., & Dill, D. L. (2019). Mebendazole for differentiation therapy of acute myeloid leukemia identified by a lineage maturation index. Scientific Reports, 9(1), Article 16775. https://doi.org/10.1038/s41598-019-53290-3